Welcome to our dedicated page for Novanta SEC filings (Ticker: NOVTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Novanta's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Novanta's regulatory disclosures and financial reporting.
Novanta Inc. Chief Executive Officer Matthijs Glastra reported an open‑market sale of 7,500 shares of common stock on February 10, 2026 at a weighted‑average price of $145.04 per share. The sale was made under a pre‑established Rule 10b5‑1 trading plan adopted on September 11, 2025.
Following this transaction, Glastra beneficially owns 57,367 Novanta shares directly and 54,382 shares indirectly through the Matthijs Glastra 2021 Irrevocable Trust, for which his spouse serves as trustee.
Novanta, Inc. has a new Rule 144 notice covering a planned sale of 7,500 shares of its common stock. The shares are to be sold through Merrill Private Wealth Management on NASDAQ, with an aggregate market value of 1087500 and 35775123 shares outstanding.
The shares to be sold were acquired as restricted stock units from Novanta, Inc. on 02/24/2022 (1084 shares), 01/03/2023 (4679 shares), and 01/02/2025 (1737 shares), all as equity compensation. A separate table shows that Matthijs Glastra has sold 323, 6177, 7500, and 6500 common shares in the past 3 months for gross proceeds of 41990, 803010, 1050000, and 877500.
Novanta Inc. Chief Executive Officer Matthijs Glastra reported selling a total of 6,500 shares of Novanta common stock on February 2, 2026. The sales were executed in several trades at weighted-average prices between $134.52 and $137.38 per share.
The transactions were made under a pre-established Rule 10b5-1 trading plan adopted on September 11, 2025 through a trust for which the reporting person’s spouse is a trustee. Following these sales, Glastra directly held 64,867 shares and indirectly held 54,382 shares through the Matthijs Glastra 2021 Irrevocable Trust.
Matthijs Glastra filed a notice to sell 6,500 shares of Novanta, Inc. common stock under Rule 144. The shares have an aggregate market value of $878,461, are listed on NASDAQ, and the approximate sale date is 02/02/2026, using Merrill Private Wealth Management as broker.
The filing shows these shares relate to restricted stock units granted as equity compensation on 02/24/2023, 02/26/2024, and 01/02/2025. It also lists recent sales of Novanta common stock by the same person during the past three months, including transactions on 01/08/2026, 01/09/2026, and 01/21/2026 with disclosed gross proceeds.
Novanta Inc.'s Chief Financial Officer Robert Buckley reported an option exercise and share sale in company stock. On 01/21/2026, he exercised a stock option for 1,423 shares of common stock at an exercise price of $14.13 per share and then sold 1,423 shares of common stock at a weighted-average price of $140.1435 per share under transaction code "S." The sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on March 13, 2025.
Following these transactions, Buckley directly held 91,034 shares of Novanta common stock and had 11,380 stock options remaining. He also had indirect beneficial ownership of 36,219 shares of common stock held through the Buckley Family Irrevocable Trust.
Novanta Inc. disclosed that a trust associated with Chief Executive Officer and director Matthijs Glastra sold common stock under a pre-established trading plan. On January 21, 2026, the entity sold 7,500 shares of Novanta common stock at $140 per share in an open-market transaction. After this sale, Glastra remained beneficial owner of 71,367 shares held directly, and 54,382 shares held indirectly through the Matthijs Glastra 2021 Irrevocable Trust. The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on September 11, 2025 through a trust for which the reporting person’s spouse is a trustee.
The holder of NOVT common stock has filed a Rule 144 notice to sell 43,920 shares. The planned sale is to be executed through J.P. Morgan Securities LLC on Nasdaq, with an approximate sale date of 01/21/2026. The filing shows these shares were acquired through a mix of stock option exercise on 01/21/2026 and multiple compensation awards from the issuer between 2021 and 2024. The number of shares of the same class outstanding is listed as 35,775,123; this is a baseline figure, not the amount being sold.
Novanta, Inc. insider plans a new stock sale under Rule 144. Matthijs Glastra filed a notice to sell up to 7,500 shares of Novanta common stock through Merrill Private Wealth Management on NASDAQ, with an aggregate market value of $1,050,000. The filing notes that 35,775,123 Novanta shares were outstanding at the time of the notice, which is a baseline figure, not the amount being sold.
The shares to be sold were acquired as equity compensation via restricted stock units on January 2, 2024 (418 shares), February 20, 2024 (1,474 shares), and February 26, 2024 (5,608 shares), all from Novanta, Inc. In the past three months, the filer has already sold 323 Novanta common shares for gross proceeds of $41,990 and 6,177 shares for $803,010. The approximate date for the new sale is listed as January 21, 2026.
Novanta Inc. reported an equity award to its General Counsel, Alexander Manganiello. On January 15, 2026, he received 10,513 Restricted Stock Units (RSUs), each representing the right to receive one Novanta common share upon vesting. The RSUs were granted at a stated price of $0 per unit, reflecting that this is a compensation award rather than an open‑market purchase.
The RSUs vest in three equal installments on January 15, 2027, January 15, 2028, and January 15, 2029. Following this grant, Manganiello is shown as beneficially owning 10,513 derivative securities directly, all tied to Novanta common stock through these RSUs.